Médecine

Paramédical

Autres domaines


S'abonner

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles - 24/04/13

Doi : 10.1016/j.jaad.2009.07.040 
Rhoda S. Narins, MD a, , Leslie Baumann, MD b, Fredric S. Brandt, MD c, Steven Fagien, MD d, Scott Glazer, MD e, Nicholas J. Lowe, MD, FRCP f, g, Gary D. Monheit, MD h, Marta I. Rendon, MD i, Rod J. Rohrich, MD j, Wm. Philip Werschler, MD k, l
a Department of Dermatology, New York University School of Medicine, New York, New York 
b Division of Cosmetic Dermatology, University of Miami, Miami, Florida 
c private practice, Coral Gables, Florida 
d private practice, Boca Raton, Florida 
e private practice, Buffalo Grove, Illinois 
f Department of Dermatology, University of California-Los Angeles School of Medicine, Los Angeles, California 
g Clinical Research Specialists, Inc, Santa Monica, California 
h Departments of Dermatology and Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama 
i Dermatology and Aesthetic Center, Inc, Boca Raton, Florida 
j University of Texas Southwestern Medical Center, Dallas, Texas 
k Medicine/Dermatology, University of Washington School of Medicine, Seattle, Washington 
l Premier Clinical Research, Spokane, Washington 

Reprint requests: Rhoda S. Narins, MD, Dermatology Surgery and Laser Center, 222 Westchester Ave, White Plains, NY 10604.

Abstract

Background

Injectable poly-L-lactic acid (PLLA) is a synthetic, biodegradable, biocompatible polymer device.

Objective

We sought to compare the efficacy and safety of injectable PLLA with human-derived collagen in treating nasolabial fold wrinkles.

Methods

In this randomized, evaluator-blinded, parallel-group, multicenter study, subjects received injectable PLLA (n = 116) or collagen (n = 117) injections (1-4 visits, 3-week intervals). Wrinkle Assessment Scale scores were calculated at screening; posttreatment week 3; months 3, 6, 9, and 13 (injectable PLLA or collagen groups); and months 19 and 25 (injectable PLLA group). Safety data were obtained from subject interviews and case report forms.

Results

Injectable PLLA significantly improved mean Wrinkle Assessment Scale scores (all time points, P < .001). Improvements (up to 25 months after last treatment) were significantly greater (P < .001) than with collagen for posttreatment months 3 to 13.

Limitations

Mostly white women and subjects with Fitzpatrick skin types II and III were included.

Conclusion

Injectable PLLA provides well-tolerated, effective, and long-lasting (up to 25 months) nasolabial fold wrinkle correction.

Le texte complet de cet article est disponible en PDF.

Key words : aesthetic, dermal filler, injectable device, injectable poly-L-lactic acid, soft-tissue augmentation

Abbreviations used : AE, CRF, NLFW, PLLA, WAS


Plan


 Sponsored by Dermik Laboratories, a business of sanofi-aventis U.S. LLC. Editorial support for this article was also provided by Dermik Laboratories, a business of sanofi-aventis U.S. LLC, and by the editorial staff at Medicus International and Embryon.
 Disclosure: Drs Narins, Baumann, Fagien, Glazer, and Monheit were consultants for Dermik Laboratories, a business of sanofi-aventis U.S. LLC, during the time of the study. Dr Brandt receives grant support from Dermik Laboratories, a business of sanofi-aventis U.S. LLC. Dr Lowe was a consultant for and received grant support from Dermik Laboratories, a business of sanofi-aventis U.S. LLC, during the time of the study. Dr Rendon is a consultant for and receives grant support from Dermik Laboratories, a business of sanofi-aventis U.S. LLC. In addition, Dr Rendon is an advisory board member for and receives grant support from BioForm Medical Inc. Dr Werschler was a consultant, investigator, advisory board member, and speaker for Dermik Laboratories, a business of sanofi-aventis U.S. LLC, during the time of the study. Dr Rohrich has no conflicts of interest to declare.
 Clinical trial registry: NCT00444210 (comparative study); NCT00444353 (long-term follow-up).


© 2009  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 62 - N° 3

P. 448-462 - mars 2010 Retour au numéro
Article précédent Article précédent
  • Human eyelid meibomian glands and tarsal muscle are recognized by autoantibodies from patients affected by a new variant of endemic pemphigus foliaceus in El-Bagre, Colombia, South America
  • Ana Maria Abreu-Velez, Michael S. Howard, Takashi Hashimoto, Hans E. Grossniklaus
| Article suivant Article suivant
  • Epidermotropic Merkel cell carcinoma: A case series with histopathologic examination
  • Mark D’Agostino, Christina Cinelli, Robert Willard, Jeffrey Hofmann, Nathaniel Jellinek, Leslie Robinson-Bostom

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.